Publications by authors named "Emmanuel Normant"

Claim this Profile
G
G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy.
Marcelo Lima Ribeiro, Núria Profitós-Pelejà, Juliana Carvalho Santos, Pedro Blecua, Diana Reyes-Garau, Emmanuel Normant

Front Immunol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ikaros as a downstream mediator of BCR blockade therapy in B-cell non-Hodgkin lymphoma.
Marcelo Lima Ribeiro, Emmanuel Normant, Gaël Roué

Oncoscience· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.
Yanping Yin, Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Emmanuel Normant

Clin Cancer Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non-Hodgkin Lymphoma.
Marcelo Lima Ribeiro, Diana Reyes-Garau, Meritxell Vinyoles, Núria Profitós Pelejà, Juliana Carvalho Santos, Emmanuel Normant

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Casein Kinase 1 (CK1) in Hematological Cancers.
Pavlína Janovská, Emmanuel Normant, Hari Miskin, Vítězslav Bryja

Int J Mol Sci· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a.
Marisa O Peluso, Ammar Adam, Caroline M Armet, Li Zhang, Rachel W O'Connor, Emmanuel Normant

J Immunother Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.
Rishi G Vaswani, Victor S Gehling, Les A Dakin, Andrew S Cook, Christopher G Nasveschuk, Emmanuel Normant

J Med Chem· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
Brian K Albrecht, Victor S Gehling, Michael C Hewitt, Rishi G Vaswani, Alexandre Côté, Emmanuel Normant

J Med Chem· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, design, and synthesis of indole-based EZH2 inhibitors.
Victor S Gehling, Rishi G Vaswani, Christopher G Nasveschuk, Martin Duplessis, Priyadarshini Iyer, Emmanuel Normant

Bioorg Med Chem Lett· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation.
William D Bradley, Shilpi Arora, Jennifer Busby, Srividya Balasubramanian, Victor S Gehling, Emmanuel Normant

Chem Biol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors.
Michele Ceribelli, Priscilla N Kelly, Arthur L Shaffer, George W Wright, Wenming Xiao, Emmanuel Normant

Proc Natl Acad Sci U S A· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
Andrew J Wagner, Rashmi Chugh, Lee S Rosen, Jeffrey A Morgan, Suzanne George, Emmanuel Normant

Clin Cancer Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Christoph Gloesenkamp, Bianca Nitzsche, Alice R Lim, Emmanuel Normant, Evan Vosburgh

Int J Oncol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.
David Siegel, Sundar Jagannath, David H Vesole, Ivan Borello, Amitabha Mazumder, Emmanuel Normant

Leuk Lymphoma· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
Giuseppe Floris, Maria Debiec-Rychter, Agnieszka Wozniak, Cristiana Stefan, Emmanuel Normant

Mol Cancer Ther· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations.
Giuseppe Floris, Raf Sciot, Agnieszka Wozniak, Thomas Van Looy, Jasmien Wellens, Emmanuel Normant

Clin Cancer Res· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.
Thomas De Raedt, Zandra Walton, Jessica L Yecies, Danan Li, Yimei Chen, Emmanuel Normant

Cancer Cell· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
Maurizio Scaltriti, Violeta Serra, Emmanuel Normant, Marta Guzman, Olga Rodriguez

Mol Cancer Ther· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Gaël Roué, Patricia Pérez-Galán, Ana Mozos, Mónica López-Guerra, Sílvia Xargay-Torrent, Emmanuel Normant

Blood· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.
Bonnie Tillotson, Kelly Slocum, John Coco, Nigel Whitebread, Brian Thomas, Emmanuel Normant

J Biol Chem· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy.
James R Porter, Jie Ge, John Lee, Emmanuel Normant, Kip West

Curr Top Med Chem· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD(P)H:quinone oxidoreductase 1 activity in vivo.
Mark Douglas, Alice R Lim, James R Porter, Kip West, Melissa M Pink, Emmanuel Normant

Mol Cancer Ther· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells.
Jon Patterson, Vito J Palombella, Christian Fritz, Emmanuel Normant

Cancer Chemother Pharmacol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Jens R Sydor, Emmanuel Normant, Christine S Pien, James R Porter, Jie Ge

Proc Natl Acad Sci U S A· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Jie Ge, Emmanuel Normant, James R Porter, Janid A Ali, Marlene S Dembski

J Med Chem· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis